Monoclonal antibodies are an evolving treatment modality in chronic lymphocytic leukemia that has the potential to provide more effective and safer targeted therapy. This review provides historical context and detailed analysis of current developments, as well as an outline for future prospects and expectations in this exciting new arena of therapeutics.
|Original language||English (US)|
|Number of pages||7|
|Journal||Clinical advances in hematology & oncology : H&O|
|State||Published - Feb 2004|
ASJC Scopus subject areas